Abstract:Dear editor, A 52-year-old woman presented with multiple small subcutaneous papules along the eyebrows for half a year (Figure 1A,B). Those papules developed with a delay of several weeks after permanent eyebrow makeup (PEMU). She was healthy, had no history of drug allergies, and had not taken any regular medications. The skin lesion was diagnosed as granulomatous reaction to colorant. The patient had received the local use of steroids and tacrolimus, three intramuscular injections of betamethasone and oral hydroxychloroquine, but no obvious curative effect was obtained. Then, the patient was treated with tofacitinib 5 mg orally twice a day, and the papules began to flatten within 1 week. The dose of tofacitinib was reduced to 5 mg per day after 1 month. During a follow-up of 5 months, her condition continued to improve (Figure 1C,D). There were no new lesions and no progress in the existing lesions. We monitored the blood routine, liver and kidney function, and found no obvious abnormalities. In addition, traditional interferon-gamma release assay (T-SPOT.TB) showed negative. There were no other adverse reactions. PEMU is a cosmetic tattoo that, like traditional tattoos, pierces the skin with a needle and injects pigment into the skin. Black or brown colorants used in PEMU can cause granulomatous reaction, which is reported to be an early sign of systemic sarcoidosis.1 Our patients found no manifestations of systemic sarcoidosis. The time range of granulomatous reaction in tattooing eyebrow may range from a few days to a few years. Although there is no predictive test to estimate the individual risk of adverse reaction, patch test and intradermal test may have predictive value.2 The persistence of colorants in the dermis may lead to long-term adverse reactions, which need continuous treatment. It has been reported that local or oral steroids, tacrolimus, allopurinol or laser ablation have achieved certain curative effects.3 In our case, the local use of steroids and tacrolimus, as well as the systematic use of corticosteroids and hydroxychloroquine, had no significant effect, while the systematic treatment of tofacitinib alleviated the patient's symptoms. Many chronic inflammatory skin diseases are related to the release of proinflammatory cytokines, which play a role through the intracellular Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway. JAK inhibitors have been shown to be effective in atopic dermatitis, psoriasis, lupus erythematosus, dermatomyositis, vitiligo, and alopecia areata.4 Recent reports suggest that targeted treatment of JAK–STAT pathways may lead to inflammation reduction and disease improvement of granulomatous diseases.5 Several cases have reported that the Jak1/3 inhibitor tofacitinib has achieved good efficacy and tolerance in the treatment of skin sarcoidosis and granuloma annulare.6 RNA sequencing also showed reduced expression of JAK–STAT dependent cytokines and pathways known to be essential for the development and maintenance of granuloma.6 The development of new and targeted therapies represents an exciting breakthrough in the treatment of granulomatous diseases. In conclusion, we provide single case evidence that tofacitinib is effective in the treatment of PEMU induced granulomatous reaction. Li-min Lao conceived the idea and collected patient data. Yan-hong Sun performed the original draft writing. Li-min Lao revised it critically and approved the final version to be published. We thank the patient for providing written informed consent to publication of her case details and images. None. The authors declare no conflicts of interest.

CPC06 The proof is in the ink: granulomatous tattoo reaction secondary to BRAF and MEK inhibition

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

A Case Report with an Emphasis on Etiopathogenic and Histological Features

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series

Granulomatous Reaction to Permanent Eyebrow Makeup Successfully Treated with Oral Tofacitinib

Cutaneous Adverse Reactions Associated with Tattoos and Permanent Makeup Pigments

BI04 Erupting and spontaneously vanishing moles in a new cohort of patients on BRAF inhibitor monotherapy

Tinea on a Tattoo

Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs)

Case Report: Balancing immune responses - multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma

Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem

Eruptive Milia Within a Tattoo: A Case Report and Review of the Literature

Early onset drug-induced hypersensitivity syndrome with lymphopenia, hepatitis, and normal eosinophils induced by BRAF/MEK inhibitor after immune checkpoint inhibitor therapy

Lichen planus pemphigoides after body tattooing

Abstract 2209: Tattooing and risk of melanoma: A population-based case-control study in Utah

Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report

Features of tattoo‐associated cutaneous lymphoid hyperplasia on reflectance confocal microscopy and line‐field confocal optical coherence tomography

Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission

Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

New features in MEK retinopathy

Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight